ZFIN ID: ZDB-FISH-150901-17599
Fish name: supt5hm806/m806
Genotype: supt5hm806/m806
Targeting Reagent: none
HUMAN DISEASE MODELED by supt5hm806/m806
No data available
GENE EXPRESSION
Gene expression in supt5hm806/m806
Protein expression No data available
Reporter gene expression No data available
PHENOTYPE
Phenotype in supt5hm806/m806
Phenotype Conditions Figures
hematopoietic multipotent progenitor cell amount, ameliorated chemical treatment: alvocidib Fig. 3 from Yang et al., 2016
hematopoietic multipotent progenitor cell runx1 expression amount, ameliorated chemical treatment: LY-2157299 Fig. 5 from Yang et al., 2016
hematopoietic multipotent progenitor cell runx1 expression amount, ameliorated chemical treatment: SB 505124 Fig. 5 from Yang et al., 2016
hematopoietic multipotent progenitor cell amount, ameliorated chemical treatment: SB 505124 Fig. 5 from Yang et al., 2016
hematopoietic multipotent progenitor cell amount, ameliorated chemical treatment: EC 2.7.11.22 (cyclin-dependent kinase) inhibitor Fig. 3 from Yang et al., 2016
hematopoietic multipotent progenitor cell amount, ameliorated chemical treatment: LY-2157299 Fig. 5 from Yang et al., 2016
hematopoietic multipotent progenitor cell runx1 expression decreased amount, abnormal standard conditions Fig. 1Fig. 5 from Yang et al., 2016
hematopoietic multipotent progenitor cell decreased amount, abnormal standard conditions Fig. 1Fig. 3Fig. 5 from Yang et al., 2016
hematopoietic progenitor cell differentiation decreased occurrence, abnormal standard conditions Fig. 1Fig. 3Fig. 5 from Yang et al., 2016
hematopoietic progenitor cell differentiation occurrence, ameliorated chemical treatment: alvocidib Fig. 3 from Yang et al., 2016
hematopoietic progenitor cell differentiation occurrence, ameliorated chemical treatment: EC 2.7.11.22 (cyclin-dependent kinase) inhibitor Fig. 3 from Yang et al., 2016
hematopoietic progenitor cell differentiation occurrence, ameliorated chemical treatment: LY-2157299 Fig. 5 from Yang et al., 2016
hematopoietic progenitor cell differentiation occurrence, ameliorated chemical treatment: SB 505124 Fig. 5 from Yang et al., 2016
hematopoietic stem cell differentiation decreased occurrence, abnormal standard conditions Fig. 2 from Yang et al., 2016
melanocyte absent, abnormal chemical treatment: pharmaceutical Fig. 3 from White et al., 2011
melanocyte decreased amount, abnormal standard conditions Fig. 3 from White et al., 2011
thymus T cell rag1 expression absent, abnormal standard conditions Fig. 1 from Yang et al., 2016
ventral wall of dorsal aorta runx1 expression decreased amount, abnormal standard conditions Fig. 2 from Yang et al., 2016
whole organism il1b expression decreased amount, abnormal standard conditions Fig. 4 from Yang et al., 2016
whole organism nfkbiaa expression decreased amount, abnormal standard conditions Fig. 4 from Yang et al., 2016
whole organism rela expression decreased amount, abnormal standard conditions Fig. 4 from Yang et al., 2016
whole organism irf2 expression decreased amount, abnormal standard conditions Fig. 4 from Yang et al., 2016
whole organism ifngr1l expression decreased amount, abnormal standard conditions Fig. 4 from Yang et al., 2016
whole organism ifngr1 expression decreased amount, abnormal standard conditions Fig. 4 from Yang et al., 2016
whole organism tgfbr1b expression increased amount, abnormal standard conditions Fig. 4 from Yang et al., 2016
whole organism smad2 expression increased amount, abnormal standard conditions Fig. 4 from Yang et al., 2016
whole organism tgfb1a expression increased amount, abnormal standard conditions Fig. 4 from Yang et al., 2016

CITATIONS  (6)